Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

Expression of oncogenic KrasG12D initiates lung adenomas in a mitogen-activated protein kinase (MAPK) signal-dependent manner from only a subset of cell types in the adult mouse lung. Amplification of MAPK signaling is associated with progression to malignant adenocarcinomas, but whether this is a cause or a consequence of disease progression is not known. To better understand the effects of MAPK signaling downstream of KrasG12D expression, we capitalized on the ability of Braf inhibition to selectively amplify MAPK pathway signaling in KrasG12D-expressing epithelial cells. MAPK signal amplification indeed promoted the rapid progression of established adenomas to malignant adenocarcinomas. However, we observed, surprisingly, a greater number of overall tumor-initiating events after MAPK signal amplification, due to induced proliferation of cell types that are normally refractory to KrasG12D-induced transformation. Thus, MAPK signaling in the lung is thresholded not only during malignant progression but also at the moment of tumor initiation.

[1]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[2]  A. Sweet-Cordero,et al.  MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. , 2012, Cancer research.

[3]  I. Wistuba,et al.  Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. , 2009, American journal of respiratory cell and molecular biology.

[4]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[5]  A. Berns,et al.  Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[6]  R. Cardiff,et al.  Classification of Proliferative Pulmonary Lesions of the Mouse , 2004, Cancer Research.

[7]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[8]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[9]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[10]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[11]  Hiroyuki Takahashi,et al.  Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. , 2010, Cancer cell.

[12]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[13]  A. Berns,et al.  Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. , 2011, Cancer cell.

[14]  B. Spencer‐Dene,et al.  Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance , 2013, Cancer cell.

[15]  A. Joyner,et al.  MASTR: a technique for mosaic mutant analysis with spatial and temporal control of recombination using conditional floxed alleles in mice. , 2012, Cell reports.

[16]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[17]  M. Barbacid,et al.  Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[18]  A. Sweet-Cordero,et al.  Requirement for Rac1 in a K-ras induced lung cancer in the mouse. , 2007, Cancer research.

[19]  Julian Downward,et al.  Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. , 2013, Cancer discovery.

[20]  J. Wolchok,et al.  Progression of RAS-mutant leukemia during RAF inhibitor treatment. , 2012, The New England journal of medicine.

[21]  Youngho Seo,et al.  Selective activation of p53-mediated tumour suppression in high-grade tumours , 2010, Nature.

[22]  M. Barbacid,et al.  Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival , 2010, The EMBO journal.

[23]  K. Flaherty,et al.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.

[24]  Dian Yang,et al.  Obligate progression precedes lung adenocarcinoma dissemination. , 2014, Cancer discovery.

[25]  Yun Lu,et al.  The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2 , 2014, Genes & development.

[26]  Gerald C. Chu,et al.  Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. , 2009, Cancer cell.

[27]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[28]  Yan Liu,et al.  An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. , 2012, The Journal of clinical investigation.

[29]  Francisco J. Sánchez-Rivera,et al.  Stage-specific sensitivity to p53 restoration during lung cancer progression , 2010, Nature.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[31]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[32]  J. Downward,et al.  SnapShot: Ras Signaling , 2008, Cell.

[33]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[34]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[35]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[36]  Yun Lu,et al.  Evidence for type II cells as cells of origin of K-Ras–induced distal lung adenocarcinoma , 2012, Proceedings of the National Academy of Sciences.

[37]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[38]  M. McMahon,et al.  TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis. , 2015, Cancer research.

[39]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[40]  S. Rowbotham,et al.  Diverse cells at the origin of lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[41]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[42]  M. McMahon,et al.  PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis. , 2015, Cancer research.

[43]  Shankar Srinivas,et al.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus , 2001, BMC Developmental Biology.

[44]  A. Eggermont,et al.  Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. , 2016, Cancer research.

[45]  D. Feldser,et al.  Recombinase-based conditional and reversible gene regulation via XTR alleles , 2015, Nature Communications.

[46]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[47]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[48]  R. Bernards,et al.  Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway , 2014, Proceedings of the National Academy of Sciences.

[49]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[50]  Andrew L Kung,et al.  Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. , 2003, Molecular imaging.